- Home
- FMST vs EDSA Comparison
FMST vs EDSA Comparison
Compare FMST & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | EDSA |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 51.5M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FMST | EDSA |
|---|---|---|
| Price | $0.78 | $4.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 75.3K | ★ 80.8K |
| Earning Date | 05-21-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $0.72 |
| 52 Week High | $4.57 | $20.32 |
Technical Indicators
Market Signals| Indicator | FMST | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 25.93 | 31.56 |
| Support Level | N/A | $1.34 |
| Resistance Level | $1.92 | $6.62 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 4.70 | 9.81 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an exploration company focused on the identification and development of high potential mineral opportunities in stable jurisdictions. Its Uranium properties includes Eastern Athabasca, and Blue-Sky. Its Lithium properties includes Zoro Lithium Project, JEAN LAKE LITHIUM GOLD PROJECT, Peg North Project, Grass River Claims Project, and JOL LITHIUM PROJECT.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.